These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 19668009)

  • 1. Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.
    Rubio A; Monpoux F; Huguon E; Truchi R; Triolo V; Rosenthal-Allieri MA; Deville A; Rosenthal E; Boutté P; Tran A
    J Pediatr Gastroenterol Nutr; 2009 Nov; 49(5):599-606. PubMed ID: 19668009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis.
    Akhtar MA; Mathieson K; Arey B; Post J; Prevette R; Hillier A; Patel P; Ram LJ; Van Thiel DH; Nadir A
    Eur J Gastroenterol Hepatol; 2008 Dec; 20(12):1194-204. PubMed ID: 18989143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors.
    Guaraldi G; Squillace N; Stentarelli C; Orlando G; D'Amico R; Ligabue G; Fiocchi F; Zona S; Loria P; Esposito R; Palella F
    Clin Infect Dis; 2008 Jul; 47(2):250-7. PubMed ID: 18532884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy.
    de Lédinghen V; Le Bail B; Rebouissoux L; Fournier C; Foucher J; Miette V; Castéra L; Sandrin L; Merrouche W; Lavrand F; Lamireau T
    J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):443-50. PubMed ID: 18030211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.
    Torti C; Lapadula G; Casari S; Puoti M; Nelson M; Quiros-Roldan E; Bella D; Pastore G; Ladisa N; Minoli L; Sotgiu G; Mazzotta F; Lo Caputo S; Di Perri G; Filice G; Tinelli C; Carosi G;
    BMC Infect Dis; 2005 Jul; 5():58. PubMed ID: 16018804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine.
    Manfredi R; Calza L; Chiodo F
    HIV Clin Trials; 2005; 6(6):302-11. PubMed ID: 16452064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
    Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
    Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfection.
    French AL; Benning L; Anastos K; Augenbraun M; Nowicki M; Sathasivam K; Terrault NA
    Clin Infect Dis; 2004 Aug; 39(3):402-10. PubMed ID: 15307009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and incidence of liver dysfunction and assessment of biomarkers of liver disease in HIV-infected Asian children.
    Aurpibul L; Bunupuradah T; Sophan S; Boettiger D; Wati DK; Nguyen LV; Saphonn V; Hansudewechakul R; Chokephaibulkit K; Lumbiganon P; Truong KH; Do VC; Kumarasamy N; Yusoff NK; Razali K; Kurniati N; Fong SM; Nallusamy R; Sohn AH;
    Pediatr Infect Dis J; 2015 Jun; 34(6):e153-8. PubMed ID: 25970117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated liver enzymes in HIV monoinfected patients on HIV therapy: what are the implications?
    Ingiliz P; Benhamou Y
    J HIV Ther; 2009 Mar; 14(1):3-7. PubMed ID: 19731558
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV.
    Palma P; Romiti ML; Cancrini C; Pensieroso S; Montesano C; Santucci MB; Bernardi S; Martino AM; Rossi P; Castelli-Gattinara G
    AIDS; 2007 Nov; 21(18):2465-72. PubMed ID: 18025883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy.
    Ingiliz P; Valantin MA; Duvivier C; Medja F; Dominguez S; Charlotte F; Tubiana R; Poynard T; Katlama C; Lombès A; Benhamou Y
    Hepatology; 2009 Feb; 49(2):436-42. PubMed ID: 19085967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-invasive fibrosis biomarkers - APRI and Forns - are associated with liver stiffness in HIV-monoinfected patients receiving antiretroviral drugs.
    Hasson H; Merli M; Galli L; Gallotta G; Carbone A; Messina E; Bagaglio S; Morsica G; Salpietro S; Castagna A; Lazzarin A; Uberti-Foppa C
    Liver Int; 2013 Aug; 33(7):1113-20. PubMed ID: 23534616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral therapy-related hepatotoxicity: predictors and clinical management.
    Dore G
    J HIV Ther; 2003 Nov; 8(4):96-100. PubMed ID: 14671507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of epicardial fat and alanine aminotransferase in subjects with increased visceral fat.
    Iacobellis G; Pellicelli AM; Grisorio B; Barbarini G; Leonetti F; Sharma AM; Barbaro G
    Obesity (Silver Spring); 2008 Jan; 16(1):179-83. PubMed ID: 18223632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients.
    Ryan P; Blanco F; García-Gascó P; García-Merchán J; Vispo E; Barreiro P; Labarga P; González-Lahoz J; Soriano V
    HIV Med; 2009 Jan; 10(1):53-9. PubMed ID: 19018879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors.
    Benhammou V; Warszawski J; Bellec S; Doz F; André N; Lacour B; Levine M; Bavoux F; Tubiana R; Mandelbrot L; Clavel J; Blanche S;
    AIDS; 2008 Oct; 22(16):2165-77. PubMed ID: 18832880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy.
    Moreno-Torres A; Domingo P; Pujol J; Blanco-Vaca F; Arroyo JA; Sambeat MA
    Antivir Ther; 2007; 12(2):195-203. PubMed ID: 17503662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
    Sulkowski MS; Thomas DL; Mehta SH; Chaisson RE; Moore RD
    Hepatology; 2002 Jan; 35(1):182-9. PubMed ID: 11786975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
    AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.